Discover
Zirabev (bevacizumab biosimilar) / PfizerAnvisa approves the biosimilar Zirabev (bevacizumab) [Google translation] (Pfarma) - Mar 4, 2020 - "Metastatic colorectal cancer (mCRC) Zirabev (bevacizumab), in combination with fluoropyrimidine-based chemotherapy, is indicated for the treatment of patients with metastatic colorectal carcinoma....Zirabev was approved with the same therapeutic indications currently approved for the Avastin® reference product, based on the totality of evidence, which indicates the high similarity between these two products."
Rubraca (rucaparib) / ClovisClovis Oncology announces availability and reimbursement for Rubraca (rucaparib) tablets for women with relapsed ovarian cancer in Spain (Businesswire) - Mar 2, 2020 - “Clovis Oncology, Inc…announced that Rubraca® (rucaparib) is now available and reimbursed in Spain following the Spanish Interministerial Commission on Prices of Medicines and Health Products approval of rucaparib for reimbursement. Rucaparib is now available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy…The European Union (EU) authorization is based on data from the pivotal phase 3 ARIEL3 clinical trial…”
mirvetuximab soravtansine (IMGN 853) / ImmunogenSORAYA: A Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (clinicaltrials.gov) - Mar 5, 2020 - P3; N=110; Not yet recruiting; Sponsor: ImmunoGen, Inc.
